Form 4: Provectus Biopharmaceuticals CEO Acquires Convertible Promissory Note

Edward Pershing, CEO of Provectus Biopharmaceuticals, acquired an 8% unsecured convertible promissory note that can be converted into Series D-1 Convertible Preferred Stock.

Summary

• Edward Pershing, the CEO of Provectus Biopharmaceuticals, acquired an 8% unsecured convertible promissory note on September 30, 2024.
• The note has a value of $175,000 and can be converted into Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• The note will automatically convert into Series D-1 Preferred Stock on September 30, 2025.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of Provectus Biopharmaceuticals' common stock.
• The Series D-1 Preferred Stock will automatically convert into common stock on June 26, 2026, unless converted earlier.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard financial transaction. The CEO is investing in the company, which could be seen as a positive signal, but it also increases the number of shares outstanding.

Future Outlook

The document outlines the terms of a convertible note and its potential conversion into preferred and then common stock, indicating a future equity stake for the CEO.

Industry Context

This type of transaction is common in the biopharmaceutical industry, especially for smaller companies seeking funding. Convertible notes allow investors (in this case, the CEO) to provide capital with the potential for equity upside.

Stakeholder Impact

• Shareholders may experience dilution if the convertible note is converted into common stock.
• The CEO's investment demonstrates confidence in the company's future.

Key Dates